



**STATE OF
OHIO**
BOARD OF PHARMACY

ANNUAL REPORT FY 2021 & FY 2022

July 1, 2020 - June 30, 2022

www.pharmacy.ohio.gov

OVERVIEW

MISSION

The State of Ohio Board of Pharmacy shall act efficiently, consistently, and impartially in the public interest to pursue optimal standards of practice through communication, education, legislation, licensing, and enforcement.

ABOUT THE BOARD

The State of Ohio Board of Pharmacy was established by the General Assembly in May of 1884 and consists of nine members, eight pharmacists and one member of the public, who are appointed by the Governor for terms of four years. The Board currently has a staff of ninety-nine full-time employees, including 11 pharmacists, who are responsible for carrying out day-to-day operations. The duties of the Board have grown over the years and encompass the enforcement of the following chapters of the Ohio Revised Code:

2925. – Criminal Drug Laws

3715. – Pure Food and Drug Law

3719. – Controlled Substance Act

3796. – Medical Marijuana Control Program

4729. – Pharmacy Practice Act & Dangerous Drug Distribution Act

4752. – Home Medical Equipment Services Providers

In enforcing these chapters, the Board licenses and regulates more than 100,000 professionals, including pharmacists, pharmacy interns and pharmacy technicians, and sites where drugs and home medical equipment are purchased and stored prior to delivery to a patient. The sites licensed by the Board include, but are not limited to, retail pharmacies, medical marijuana dispensaries, home medical equipment services providers, hospitals, drug wholesalers, prescriber offices, drug manufacturers, veterinary clinics, nursing homes, prisons and jails, emergency medical service organizations, medical gas distributors, and pain management clinics.

The State of Ohio Board of Pharmacy is charged with preventing, detecting, and investigating the diversion of dangerous drugs, including controlled substances. The Board investigates and presents evidence of violations of drug laws by any person and refers them for prosecution and/or administrative action. In these efforts, the Board works collaboratively with other state prescriber boards and law enforcement to conduct investigations of healthcare professionals (pharmacists, physicians, dentists, nurses, etc.) who may be in violation of Ohio law.

A LETTER FROM THE EXECUTIVE DIRECTOR

On behalf of the members of the State of Ohio Board of Pharmacy, I am pleased to present the Fiscal Year 2021 & 2022 (FY 21/22) Annual Report. Over the past two years, the Board focused its efforts to assist pharmacists, pharmacies, and other licensees during the Coronavirus (COVID-19) pandemic.

As part of these efforts, the Board issued 40 waivers to assist our licensees in meeting unique operational challenges during the pandemic. The full list of Board's COVID-19 waivers can be found at: www.pharmacy.ohio.gov/COVID.

Other highlights from FY 21 & 22 include:

Pharmacist Workload Survey - In July 2020, the State of Ohio Board of Pharmacy disseminated a workload survey to all pharmacists working in Ohio. The intent of the survey was to capture feedback on pharmacist working conditions in the state. As a result of the survey, the Board established the Pharmacist Workload Advisory Committee. The PWAC submitted policy options to address workload concerns for consideration by the full Board in June 2022. For more information on pharmacist workload and the PWAC, please visit: www.pharmacy.ohio.gov/PWAC.

Expanding Access to Naloxone - The Board purchased and installed 12 naloxone boxes strategically throughout Capitol Square and at several state office buildings. These boxes equip Ohioans with the tools needed to effectively respond to an overdose using naloxone, a life-saving drug that reverses the effects of an opioid overdose.

Supporting the Use of Technology in the Practice of Pharmacy - In March 2022, the Board finalized its pharmacy pilot program rule. This rule allows licensees to request Board approval of a pilot or research project for innovative system applications in the practice of pharmacy that are not currently permitted under Board of Pharmacy rules.

Banning Novel Substances Contributing to Overdose Deaths - In April 2022, the Board, in collaboration with the Governor's Office, filed emergency rules to classify seven novel opioid compounds as Schedule I Controlled Substances.


Launched Virtual Law Reviews and Response Person Roundtables - In 2021, the Board hosted its first virtual law reviews and responsible person roundtables. Over 500 pharmacists, pharmacy interns, pharmacy technicians, and pharmacy compliance staff attended the virtual events.

Thank you for taking the time to review the State of Ohio Board of Pharmacy's Fiscal Year 2021 & 2022 Annual Report. The Board remains committed to protecting the health and safety of all Ohioans.

Sincerely,



Steven W. Schierholt, Esq.
Executive Director



LICENSING

The Licensing Department's responsibilities include processing of all licensure and registration applications, all verifications of good standing, organization of all reciprocity reviews and support to all field agents, inspectors, and specialists. The Board licenses/ registers all of the following:

- Pharmacists, pharmacy interns, and pharmacy technicians.
- Terminal Distributors of Dangerous Drugs (TDDD): Sites where dangerous drugs are purchased and stored prior to delivery to a patient such as retail pharmacies, hospitals, prescriber offices, veterinary clinics, nursing homes, prisons and jails, emergency medical service organizations and pain management clinics.
- Distributors of Dangerous Drugs: Sites who are engaged in the sale of dangerous drugs at wholesale. A distributor of dangerous drugs includes the following license types: manufacturer of dangerous drugs, outsourcing facility, third-party logistics provider, repackager of dangerous drugs, and wholesale distributor of dangerous drugs (includes broker and virtual wholesaler).
- Home Medical Equipment Service Providers (HME): Sites who are engaged in the sale, delivery, installation, maintenance, replacement, or demonstration of home medical equipment.

FY 2021 AND 2022 ACCOMPLISHMENTS

- Conducted the first biennial renewal for registered and certified pharmacy technicians, which resulted in over 15,000 renewed registrations.
- Implemented a pharmacy technician reciprocity process that allows technicians working in other states to quickly obtain a technician registration in Ohio.
- As part of the state's coronavirus response efforts, The Board issued the following resolutions:
 - Authorized expedited onboarding for pharmacy technician trainee applicants by granting conditional approval to work under certain conditions. As a result, the Licensing Department issued conditional approval for over 2,000 trainee applicants.
 - Authorized expedited licensure of drug distributor applicants to ensure continuity of the drug supply chain. As a result, the Licensing Department issued over 200 drug distributor licenses pursuant to the resolution.

FY 2021 Licensing Statistics

Type of License	FY 2021 Active	FY 2021 New
Pharmacist	21,882	920
Pharmacy Intern	4,343	931
Pharmacy Technician	37,075	7,885
Terminal Distributors	23,831	1,927
Drug Distributors	2,237	209
HME Service Providers	1,055	71
Medical Marijuana Dispensary Employees	2,311	1,161
Dispensary - Provisional	3	1
Dispensary - Certificate of Operation	70*	18*
Total	92,807	13,123

**Refers to the total dispensary licenses issued, this includes new licenses that have been issued due to Change of Ownership.*

FY 2022 Licensing Statistics

Type of License	FY 2022 Active	FY 2022 New
Pharmacist	23,267	1,337
Pharmacy Intern	5,132	788
Pharmacy Technician	43,783	9,912
Terminal Distributors	24,768	1,941
Drug Distributors	2,228	254
HME Service Providers	1,097	56
Medical Marijuana Dispensary Employees	2,880	1,259
Dispensary - Provisional	74	73
Dispensary - Certificate of Operation	89*	21*
Total	103,318	15,641

**Refers to the total dispensary licenses issued, this includes new licenses that have been issued due to Change of Ownership.*

COMPLIANCE AND ENFORCEMENT

The primary responsibility of the Compliance & Enforcement Department, in coordination with the Legal Department, is the investigation and prosecution of administrative violations and criminal acts perpetrated by license holders and applicants, as well as prescription drug-related crimes committed by healthcare professionals and the public. Department staff also perform pharmacy inspections; train pharmacy, medical, and law enforcement personnel; and assist outside agencies with criminal investigations involving prescription drugs.


FY 2021 ACCOMPLISHMENTS

- In Northeast Ohio, a joint investigation with state and federal counterparts led to a physician pleading guilty to 79 counts, including illegal distribution and possession of drugs, Medicaid fraud, and grand theft.
- Medical Marijuana Control Program Agents received a complaint that a dispensary employee was engaged in the sale of illegal drugs. During a joint investigation with local and federal authorities, it was discovered that the employee was trafficking in marijuana and other illicit drugs. The employee was subsequently indicted on trafficking in marijuana, possession of marijuana, possessing criminal tools, and aggravated possession of drugs. The employee's patient and support employee registration were also suspended indefinitely.
- Board staff conducted a total of 1,470 inspections and issued 86 written warnings in FY 21.

FY 2021 NEW CASES BY TYPE

Case Type	# of New Cases
Theft of Drugs	306
Minimum Qualifications for Licensure	207
Suspicious Purchases	206
Error in Dispensing	174
Background Investigation	155
Deception to Obtain Dangerous Drugs	129
MMJ Background Investigation	120
Questionable Dispensing	80
Late Renewal of TDDD/WDDD License	21

FY 2021 CASE SUSPECTS BY TYPE



Administrative actions taken against a licensee can range from permanent revocation to imposition of fines or, for pharmacists, interns and technicians, additional continuing education requirements. Suspensions and probations are also utilized, particularly in cases of substance abuse where rehabilitation is deemed possible.

The table below and on the next page provide a summary of administrative actions taken by the Board in FY 2021.

ADMINISTRATIVE ACTIONS IN FY 2021 - PHARMACY	
Summary Suspensions* (Total)	38
Summary Suspensions (Pharmacy Technicians)	31
Summary Suspensions (Pharmacists)	6
Summary Suspensions (Interns)	0
Summary Suspensions (TDDD)	1
Summary Suspensions (Drug Distributors)	0
Summary Suspensions (OARRS)	0
Citations Issued (Includes Summary Suspensions)	370
Proposals to Deny	31
Settlement Agreements	234
License Revocations	46
Pharmacist Probation	49

**A summary suspension is a method of immediately suspending a license or registration. It is utilized if the alleged offense presents "a danger of immediate and serious harm to others." Licensees and registrants that are summarily suspended are still entitled to a full hearing by the Board in accordance with Chapter 119. of the Revised Code.*

ADMINISTRATIVE ACTIONS IN FY 2021 - MEDICAL MARIJUANA	
Summary Suspensions (Total)	30
Summary Suspensions (Dispensary Employees)	6
Summary Suspensions (Patients)	21
Summary Suspensions (Caregivers)	3
Citations (Total)⁺	5
Citation Issued (Dispensary Employees)	2
Citation Issued (Patients)	3
Citation Issued (Caregivers)	0
Proposals to Deny	25
Proposal to Deny (Dispensary Employees)	4
Proposal to Deny (Patients)	0
Proposal to Deny (Caregivers)	25
License Revocations	46

⁺Indicates discipline against a licensee, does not include summary suspensions.


FY 2022 ACCOMPLISHMENTS

- Board agents worked closely with the United States Department of Justice Appalachian Region Prescription Opioid Strike Force to identify and investigate prescribers engaged in possible criminal activity.
- Board agents contributed to overdose fatality review committees in Franklin and Cuyahoga counties where they examined overdose data to identify possible interventions to reduce drug overdose deaths.
- Board agents secured the indictment of an office-based opioid treatment physician on five counts of trafficking in drugs and one count of engaging in a pattern of corrupt activity. The physician in question was prescribing controlled substances to patients without a legitimate medical purpose.
- Compliance personnel assisted in efforts led by the National Association of Boards of Pharmacy (NABP) and Partnership for Drug Supply Chain Security Act (DSCSA) Governance to implement a DSCSA interoperability system that complies with federal law.
- Board staff conducted a total of 2,157 inspections and issued 861 written responses in FY 22.

FY 2022 NEW CASES BY TYPE

Case Type	# of New Cases
Theft of Drugs	233
Minimum Qualifications for Licensure	184
Error in Dispensing	152
Drug Security	149
Deception to Obtain Dangerous Drugs	145
Illegal Drug Sales	144
Suspicious Purchases	99
Questionable Dispensing	83
MMJ Dispensary Background	80
MMJ Background Investigation	65

FY 2022 CASE SUSPECTS BY TYPE



ADMINISTRATIVE ACTIONS IN FY 2022 - PHARMACY	
Summary Suspensions* (Total)	28
Summary Suspensions (Pharmacy Technicians)	15
Summary Suspensions (Pharmacists)	12
Summary Suspensions (Interns)	0
Summary Suspensions (TDDD)	1
Summary Suspensions (Drug Distributors)	0
Summary Suspensions (OARRS)	0
Citations Issued (Includes Summary Suspensions)	241
Proposals to Deny Licensure/Registration	20
Settlement Agreements	202
License Revocations	17

**A summary suspension is a method of immediately suspending a license or registration. It is utilized if the alleged offense presents "a danger of immediate and serious harm to others." Licensees and registrants that are summarily suspended are still entitled to a full hearing by the Board in accordance with Chapter 119. of the Revised Code.*

ADMINISTRATIVE ACTIONS IN FY 2022 - MEDICAL MARIJUANA	
Summary Suspensions (Total)	1
Summary Suspensions (Dispensary Employees)	0
Summary Suspensions (Patients)	1
Summary Suspensions (Caregivers)	0
Citations (Total)⁺	67
Citation Issued (Dispensary Employees)	15
Citation Issued (Patients)	1
Citation Issued (Caregivers)	18
Citation Issued (Dispensary)	33
Proposals to Deny	46
Proposal to Deny (Dispensary Employees)	5
Proposal to Deny (Patients)	0
Proposal to Deny (Caregivers)	15
Proposal to Deny (Dispensary)	26
Citations Issued Total (Includes Summary Suspensions)	67
License Revocations	10
Dispensary Settlement Agreements	0

⁺Indicates discipline against a licensee, does not include summary suspensions.

POLICY AND COMMUNICATIONS

The Policy and Communications Department is responsible for the development and implementation of strategies to advance the Board's policy initiatives and outreach to external stakeholders, including all of the following:

- Articulating the Board's position on legislation proposed by the General Assembly.
- Facilitating the administrative rules process by coordinating the Board's Rules Review Committee, submission of proposed rules to the Common Sense Initiative, and rule filings with the Joint Committee on Agency Rule Review.
- Coordinating the Board's responses to legislative committee requests and other inquiries from individual members and General Assembly staff.
- Assisting with the implementation of legislative and regulatory changes.
- Developing educational materials and guidance for licensees on Board initiatives and policy changes.
- Serving as a liaison to the public and the media on the role of the Board in protecting the health and safety of Ohioans.

FY 2021 & FY 2022 ACCOMPLISHMENTS

- As part of the Board's COVID-19 response efforts, the Policy and Communications Department sent more than 3 million email updates to licensees in FY 21.
- Facilitated the inclusion of several policy proposals as part of HB 110, Ohio's Biennial Budget, including authorizing the establishment of county or regional drug overdose fatality and suicide fatality review committees.
- Successful development and implementation of new rules governing prescriber compounding, non-resident pharmacies, institutional facilities, and outpatient pharmacies.
- The continued opioid epidemic across the United States has made it more important than ever to destigmatize opioid addiction and make naloxone products readily available to people in need. The Board created a continuing education course that focuses on basic information on the dispensing of naloxone products in pharmacies by pharmacists or pharmacy interns in the State of Ohio without a prescription pursuant to a physician-authorized protocol. For more information, visit: [**www.pharmacy.ohio.gov/naloxonereview**](http://www.pharmacy.ohio.gov/naloxonereview).

OHIO AUTOMATED RX REPORTING SYSTEM



OHIO AUTOMATED RX REPORTING SYSTEM

To address the growing misuse and diversion of prescription drugs, the State of Ohio Board of Pharmacy created Ohio's prescription drug monitoring program, known as the Ohio Automated Rx Reporting System (OARRS). Established in 2006, OARRS collects information on all outpatient prescriptions for controlled substances (and two non-controlled drugs, gabapentin and naltrexone)

dispensed by Ohio-licensed pharmacies and personally furnished by licensed prescribers in Ohio. Drug wholesalers are also required to submit information on all controlled substances sold to an Ohio licensed pharmacy or prescriber. The data is reported every 24 hours (except wholesalers who report monthly) and is maintained in a secure database.

For more information on OARRS, please review the most recent OARRS Annual Report: www.pharmacy.ohio.gov/OARRS2021

FY 2021 & FY 2022 ACCOMPLISHMENTS

- OARRS was the first PDMP in the country to receive certification from the Centers for Medicare and Medicaid Services. As a certified system, OARRS now receives CMS funding to support the system and share data with the Ohio Department of Medicaid.
- In FY 21, the Board received a \$1.3 million dollar grant from the U.S. Department of Justice to maintain and enhance the Board's capability to analyze PDMP data to identify controlled substance drug diversion and to maintain and enhance the agency's ability to ensure timely and accurate PDMP data.
- In FY 22, the Board received a \$1.4 million dollar grant from the U.S. Department of Justice to promote collaboration among the Board, law enforcement, and prosecutors by funding four Board of Pharmacy Enforcement Agents (OARRS Agents) to conduct criminal investigations of drug diversion utilizing data from OARRS.
- In collaboration with the Ohio Department of Mental Health and Addiction Services, OARRS now receives data on who is being actively treated at any of Ohio's opioid treatment programs. This information, which is only available to healthcare provider account holders, closes a blind spot for clinicians and improves overall care coordination.

MEDICAL MARIJUANA

As one of the three state agencies charged with the implementation of the Ohio Medical Marijuana Control Program (MMCP), the Board is responsible for:

- The patient and caregiver registry;
- Licensing of retail dispensaries;
- Licensing of dispensary employees;
- Managing the toll-free helpline;
- Approving new forms of medical marijuana.

The Board is responsible for reviewing and assigning product identifications for medical marijuana products.



MMCP Products Available by FY

Forms	IDs Assigned FY 21	IDs Assigned FY 22
Tier I plant material	2,942	1,740
Tier II plant material	1,505	1,698
Metered oil or solid for vaporization	2,243	4,268
Edibles for oral administration	1,130	1,793
Lotions	463	53
Capsule for oral administration	79	139
Tinctures	55	48
Transdermal patches	46	26
Oil for oral administration	33	45
Ointments	15	11
Plant Material for Vaporization	-	3,591*
Sublingual for Oral Administration ⁺	-	25

**In FY 22, the Board consolidated the tiered plant material. +Sublingual for Oral Administration was added as a new form in FY 22.*

FY 2021 & FY 2022 ACCOMPLISHMENTS

- To assist patients during the COVID-19 pandemic, the Board issued waivers permitting curb-side pick-up and online ordering. Due to the successful implementation of these waivers, the Board made these changes permanent.
- The Board issued a second Request for Applications and issued an additional 70 provisional dispensary licenses. For more information on the second RFA process visit: www.pharmacy.ohio.gov/RFA2FAQ.
- By the end of FY 22, the MMCP reported over 285,621 registered patients, with 148,950 patients with both an active recommendation and active registration. Additional program updates may be accessed by visiting: www.pharmacy.ohio.gov/mmupdate.

STATEMENT OF ACTIVITIES

FOR STATE FISCAL YEAR 2021 (JULY 1, 2020 - JUNE 30, 2021)

FY 2021 Revenue

Fund 4K90 (Operating Expenses) License fees and other assessments as well as various fines, forfeited bonds and bail collected by the State Board of Pharmacy that are not credited to Fund 4A50.	\$12,637,985
Fund 4A50 (Drug Law Enforcement) Fines and bail or property forfeitures that result from the Board's drug law enforcement efforts.	\$29,526
Fund 3HD0 (Pharmacy Federal Grants) Harold Rogers Prescription Monitoring Program grants distributed by the U.S. Department of Justice, Office of Justice Programs.	\$758,039
Fund 3HH0 (OARRS Integration) Grant money received from Medicaid to support OARRS integration with medical record systems.	\$2,054,107
Fund 3HM0 (Equitable Sharing Treasury) Money derived from the proceeds of investigations worked with federal agencies under the administrative umbrella of the Department of the Treasury	\$104
Fund 3HN0 (Equitable Sharing Justice) Money derived from the proceeds of investigations worked with federal agencies under the administrative umbrella of the Department of Justice	\$886
Fund 5SG0 (Drug Database) Donations and grant subawards used to make improvements to OARRS under ORC 4729.83.	\$139,499
Fund 5SY0 (Medical Marijuana Control Program) Revenue comes from fees paid by dispensaries and patients.	\$10,298,742
TOTAL REVENUE FY 2021	\$25,918,888

FY 2021 Expenses

Fund 4K90 (Operating Expenses) Used by the Board to administer and enforce laws governing the legal distribution of dangerous drugs and the practice of pharmacy. A portion of this funding also goes to support the operation of Ohio's prescription drug monitoring program known as the Ohio Automated Rx Reporting System (OARRS).	\$10,107,307
Fund 4A50 (Drug Law Enforcement) Used by the Board for drug law enforcement purposes only.	\$14,173
Fund 3HD0 (Pharmacy Federal Grants) Harold Rogers Prescription Monitoring Program grants distributed by the U.S. Department of Justice, Office of Justice Programs.	\$742,120
Fund 3HH0 (OARRS Integration HITECH) Grant money received from the Ohio Department of Medicaid to support OARRS integration with medical record systems.	\$2,050,824
Fund 3HN0 (Equitable Sharing Justice) Money derived from the proceeds of investigations worked with federal agencies under the administrative umbrella of the Department of Justice	\$108,084
Fund 5SG0 (Drug Database) Implement enhancements to OARRS.	\$128,912
Fund 5SY0 (Medical Marijuana Control Program) Used by the Board to implement the Medical Marijuana Control Program under ORC Chapter 3796.	\$2,358,914
TOTAL EXPENSES FY 2021	\$15,510,334

[1] Expenses reflect actual cash disbursements during FY 2021 and include some expenses budgeted with FY 2020 appropriation. Similarly, some expenses budgeted with FY 2021 appropriation will be disbursed in FY 2022 and reflected on that year's annual report.

[2] Pursuant to section 119.092(E), the State of Ohio Board of Pharmacy did not pay any fees to a prevailing eligible party in Fiscal Year 2021.

STATEMENT OF ACTIVITIES

FOR STATE FISCAL YEAR 2022 (JULY 1, 2021 - JUNE 30, 2022)

FY 2022 Revenue

Fund 4K90 (Operating Expenses) License fees and other assessments as well as various fines, forfeited bonds and bail collected by the State Board of Pharmacy that are not credited to Fund 4A50.	\$11,186,112
Fund 4A50 (Drug Law Enforcement) Fines and bail or property forfeitures that result from the Board's drug law enforcement efforts.	\$55,362
Fund 3HD0 (Pharmacy Federal Grants) Harold Rogers Prescription Monitoring Program grants distributed by the U.S. Department of Justice, Office of Justice Programs.	\$961,924
Fund 3HH0 (OARRS Integration) Grant money received from Medicaid to support OARRS integration with medical record systems.	\$1,790,795
Fund 3HM0 (Equitable Sharing Treasury) Money derived from the proceeds of investigations worked with federal agencies under the administrative umbrella of the Department of the Treasury	\$84
Fund 3HN0 (Equitable Sharing Justice) Money derived from the proceeds of investigations worked with federal agencies under the administrative umbrella of the Department of Justice	\$11,291
Fund 5SG0 (Drug Database) Donations and grant subawards used to make improvements to OARRS under ORC 4729.83.	\$84,951
Fund 5SY0 (Medical Marijuana Control Program) Revenue comes from fees paid by dispensaries and patients.	\$20,550,007
TOTAL REVENUE FY 2022	\$34,640,526

FY 2022 Expenses

Fund 4K90 (Operating Expenses) Used by the Board to administer and enforce laws governing the legal distribution of dangerous drugs and the practice of pharmacy. A portion of this funding also goes to support the operation of Ohio's prescription drug monitoring program known as the Ohio Automated Rx Reporting System (OARRS).	\$11,979,065
Fund 4A50 (Drug Law Enforcement) Used by the Board for drug law enforcement purposes only.	\$0
Fund 3HD0 (Pharmacy Federal Grants) Harold Rogers Prescription Monitoring Program grants distributed by the U.S. Department of Justice, Office of Justice Programs.	\$997,353
Fund 3HH0 (OARRS Integration HITECH) Grant money received from the Ohio Department of Medicaid to support OARRS integration with medical record systems.	\$1,809,551
Fund 3HN0 (Equitable Sharing Justice) Money derived from the proceeds of investigations worked with federal agencies under the administrative umbrella of the Department of Justice	\$0
Fund 5SG0 (Drug Database) Implement enhancements to OARRS.	\$84,950
Fund 5SY0 (Medical Marijuana Control Program) Used by the Board to implement the Medical Marijuana Control Program under ORC Chapter 3796.	\$3,061,131
TOTAL EXPENSES FY 2022	\$17,932,050

[1] Expenses reflect actual cash disbursements during FY 2022 and include some expenses budgeted with FY 2021 appropriation. Similarly, some expenses budgeted with FY 2022 appropriation will be disbursed in FY 2023 and reflected on that year's annual report.

[2] Pursuant to section 119.092(E), the State of Ohio Board of Pharmacy did not pay any fees to a prevailing eligible party in Fiscal Year 2022.



The State of Ohio Board of Pharmacy is committed to protecting the health and safety of all Ohioans through the administration and enforcement of laws governing the legal distribution of dangerous drugs and the practice of pharmacy. Should you need any assistance or additional information, please do not hesitate to contact the Board.

Board Members

Shawn C. Wilt, R.Ph., President
Trina Buettner, R.Ph., Vice President
Mindy Ferris, R.Ph.
Jason M. George, PharmD
N. Victor Goodman, Public Member
Tod J. Grimm, R.Ph., MBA
Jeff Huston, BPharm, PharmD, R.Ph.
D. Rich Miller III, B.S., R.Ph.
Christine Pfaff, R.Ph.

State of Ohio Board of Pharmacy
77 South High Street
17th Floor
Columbus, OH 43215
Phone: 614-466-4143
www.pharmacy.ohio.gov/contact